Safety and efficacy of everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis: a case series study

Safety and efficacy of Everolimus in patients with renal angiomyolipoma associated with tuberous sclerosis: a case series study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039523

Enrollment

Unknown

Registered

2020-10-30

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberous sclerosis complex

Interventions

case series:everolimus

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Patients must meet all of the following criteria to be included: (1) TsC-RAML was diagnosed; (2) CT or MRI showed that the longest diameter of TSC-RAML was >= 3 cm; (3) Take everolimus (brand name: AFINITOR); (4) With good compliance, complete follow-up information can be obtained.

Exclusion criteria

Exclusion criteria: Patients who meet one of the following criteria will be excluded: (1) The dosage of everolimus cannot be obtained; (2) The primary indicator cannot be obtained; (3) The demographic information cannot be obtained.

Design outcomes

Primary

Measure	Time frame
Tumor size;	—

Countries

China

Contacts

Public ContactZhou Ying

Peking University First Hospital

zhouying0321@126.com+86 10-66110802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026